Keyphrases
FDG PET-CT
100%
Immune Monitoring
100%
Ipilimumab
100%
Nivolumab
100%
Tumoral
100%
Advanced Melanoma
100%
Systemic Immune Response
100%
In(III)
20%
Immune-related Adverse Events
20%
Clinical Presentation
13%
Metabolic Tumor Volume
13%
Metabolic Disease
13%
Response Assessment
13%
Extracranial
13%
IrAE
13%
Secondary Progression
13%
Treatment Monitoring
6%
Clinically Significant
6%
Overall Survival
6%
Median Progression-free Survival
6%
Consecutive Patients
6%
CT Findings
6%
Am(III)
6%
Clinical Diagnosis
6%
Immune Checkpoint Inhibitors
6%
Response Evaluation
6%
CT Manifestations
6%
Metabolic Response
6%
Gastroenteritis
6%
Response Monitoring
6%
Nivolumab Plus Ipilimumab
6%
Endocrinopathy
6%
Multiple Systems
6%
Immune Checkpoint Inhibitor Therapy
6%
FDG-PET Scan
6%
Best Overall Response
6%
Complete Metabolic Response
6%
Long-term Treatment Outcomes
6%
PET Response Criteria in Solid Tumors
6%
Medicine and Dentistry
Positron Emission Tomography-Computed Tomography
100%
Immune Response
100%
Ipilimumab
100%
Nivolumab
100%
Melanoma
100%
Immune-Related Adverse Events
18%
Neoplasm
12%
Immune Checkpoint Inhibitor
12%
Water-Electrolyte Imbalance
12%
Treatment Response
6%
Progression Free Survival
6%
Overall Survival
6%
Solid Malignant Neoplasm
6%
Endocrine Disease
6%
Enterocolitis
6%
Polyethylene Terephthalate
6%
X-Ray Computed Tomography
6%
Pharmacology, Toxicology and Pharmaceutical Science
Melanoma
100%
Nivolumab
100%
Ipilimumab
100%
Polyethylene Terephthalate
100%
Adverse Event
17%
Neoplasm
11%
Immune Checkpoint Inhibitor
11%
Metabolic Disorder
11%
Progression Free Survival
5%
Overall Survival
5%
Solid Malignant Neoplasm
5%
Endocrine Disease
5%
Enterocolitis
5%
Immunology and Microbiology
Immune Response
100%
Positron Emission Tomography-Computed Tomography
100%
Nivolumab
100%
Ipilimumab
100%
Pretreatment
18%
Metabolic Tumor Volume
12%
Immune Checkpoint Inhibitor
12%
Overall Survival
6%
Enterocolitis
6%
Progression Free Survival
6%
X-Ray Computed Tomography
6%